Hemolytic-Uremic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hemolytic-uremic syndrome markets are expected to exhibit a CAGR of 4.7% during 2024-2034.
The hemolytic-uremic syndrome market has been comprehensively analyzed in IMARC's new report titled "Hemolytic-Uremic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemolytic-uremic syndrome (HUS) is a rare but serious medical condition characterized by the triad of hemolytic anemia, acute kidney injury, and a low platelet count. It primarily affects young children, although individuals of all ages can be affected. The symptoms of HUS typically start with gastrointestinal issues, such as diarrhea, often bloody, along with abdominal pain and vomiting. As the condition progresses, anemia can lead to fatigue and paleness, while kidney involvement might cause decreased urine output, swelling, and high blood pressure. The low platelet count can result in easy bruising and bleeding tendencies. The diagnosis of HUS involves a combination of clinical assessment and laboratory tests. Blood workups are also recommended to reveal anemia, a low platelet count, and elevated levels of waste products, including creatinine and urea. Stool samples are further tested for bacteria like Escherichia coli (E.coli) that can trigger the condition, particularly in cases linked to a preceding gastrointestinal infection.
The increasing cases of bacterial infections, which produce toxins that damage blood vessels and lead to the destruction of red blood cells, are primarily driving the hemolytic-uremic syndrome market. In addition to this, the inflating utilization of efficacious pharmaceutical interventions, such as plasma exchange and infusion, antibiotics, corticosteroids, etc., is also creating a positive outlook for the market. These treatments aim to control symptoms, mitigate organ damage, and reduce mortality rates in individuals suffering from the illness. Moreover, the widespread adoption of renal replacement therapies, including hemodialysis and peritoneal dialysis, since they help in managing fluid overload, electrolyte imbalance, and removing waste products from the bloodstream, is further bolstering the market growth. Apart from this, the rising usage of advanced technologies, such as machine learning and artificial intelligence, in diagnosing HUS through the identification of relevant biomarkers and predictive analysis is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine, tailoring treatment regimens based on patient genetic predispositions and disease manifestations, is also augmenting the market growth. Furthermore, the escalating application of complement-targeted therapies, which block or inhibit specific components of the complement cascade to regulate the inflammatory response and prevent damage to vital organs, is expected to drive the hemolytic-uremic syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hemolytic-uremic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemolytic-uremic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemolytic-uremic syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hemolytic-uremic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hemolytic-uremic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current hemolytic-uremic syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the hemolytic-uremic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hemolytic-uremic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hemolytic-uremic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hemolytic-uremic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of hemolytic-uremic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hemolytic-uremic syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hemolytic-uremic syndrome across the seven major markets?
What is the size of the hemolytic-uremic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hemolytic-uremic syndrome?
What will be the growth rate of patients across the seven major markets?
Hemolytic-Uremic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hemolytic-uremic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hemolytic-uremic syndrome market?
What are the key regulatory events related to the hemolytic-uremic syndrome market?
What is the structure of clinical trial landscape by status related to the hemolytic-uremic syndrome market?
What is the structure of clinical trial landscape by phase related to the hemolytic-uremic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the hemolytic-uremic syndrome market?
The hemolytic-uremic syndrome market has been comprehensively analyzed in IMARC's new report titled "Hemolytic-Uremic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemolytic-uremic syndrome (HUS) is a rare but serious medical condition characterized by the triad of hemolytic anemia, acute kidney injury, and a low platelet count. It primarily affects young children, although individuals of all ages can be affected. The symptoms of HUS typically start with gastrointestinal issues, such as diarrhea, often bloody, along with abdominal pain and vomiting. As the condition progresses, anemia can lead to fatigue and paleness, while kidney involvement might cause decreased urine output, swelling, and high blood pressure. The low platelet count can result in easy bruising and bleeding tendencies. The diagnosis of HUS involves a combination of clinical assessment and laboratory tests. Blood workups are also recommended to reveal anemia, a low platelet count, and elevated levels of waste products, including creatinine and urea. Stool samples are further tested for bacteria like Escherichia coli (E.coli) that can trigger the condition, particularly in cases linked to a preceding gastrointestinal infection.
The increasing cases of bacterial infections, which produce toxins that damage blood vessels and lead to the destruction of red blood cells, are primarily driving the hemolytic-uremic syndrome market. In addition to this, the inflating utilization of efficacious pharmaceutical interventions, such as plasma exchange and infusion, antibiotics, corticosteroids, etc., is also creating a positive outlook for the market. These treatments aim to control symptoms, mitigate organ damage, and reduce mortality rates in individuals suffering from the illness. Moreover, the widespread adoption of renal replacement therapies, including hemodialysis and peritoneal dialysis, since they help in managing fluid overload, electrolyte imbalance, and removing waste products from the bloodstream, is further bolstering the market growth. Apart from this, the rising usage of advanced technologies, such as machine learning and artificial intelligence, in diagnosing HUS through the identification of relevant biomarkers and predictive analysis is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine, tailoring treatment regimens based on patient genetic predispositions and disease manifestations, is also augmenting the market growth. Furthermore, the escalating application of complement-targeted therapies, which block or inhibit specific components of the complement cascade to regulate the inflammatory response and prevent damage to vital organs, is expected to drive the hemolytic-uremic syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hemolytic-uremic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemolytic-uremic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemolytic-uremic syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hemolytic-uremic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hemolytic-uremic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current hemolytic-uremic syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the hemolytic-uremic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hemolytic-uremic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hemolytic-uremic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hemolytic-uremic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of hemolytic-uremic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hemolytic-uremic syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hemolytic-uremic syndrome across the seven major markets?
What is the size of the hemolytic-uremic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hemolytic-uremic syndrome?
What will be the growth rate of patients across the seven major markets?
Hemolytic-Uremic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hemolytic-uremic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hemolytic-uremic syndrome market?
What are the key regulatory events related to the hemolytic-uremic syndrome market?
What is the structure of clinical trial landscape by status related to the hemolytic-uremic syndrome market?
What is the structure of clinical trial landscape by phase related to the hemolytic-uremic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the hemolytic-uremic syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEMOLYTIC-UREMIC SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEMOLYTIC-UREMIC SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEMOLYTIC-UREMIC SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HEMOLYTIC-UREMIC SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEMOLYTIC-UREMIC SYNDROME - UNMET NEEDS
10 HEMOLYTIC-UREMIC SYNDROME - KEY ENDPOINTS OF TREATMENT
11 HEMOLYTIC-UREMIC SYNDROME - MARKETED PRODUCTS
11.1 List of Hemolytic-Uremic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Soliris (Eculizumab) - Alexion AstraZencea Rare Disease
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ultomiris (Ravulizumab) - Alexion AstraZeneca Rare Disease
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEMOLYTIC-UREMIC SYNDROME - PIPELINE DRUGS
12.1 List of Hemolytic-Uremic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Crovalimab - Chugai Pharmaceutical/Roche
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Iptacopan - Novartis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 NM8074 - NovelMed Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEMOLYTIC-UREMIC SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEMOLYTIC-UREMIC SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEMOLYTIC-UREMIC SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hemolytic-Uremic Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hemolytic-Uremic Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hemolytic-Uremic Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hemolytic-Uremic Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hemolytic-Uremic Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hemolytic-Uremic Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hemolytic-Uremic Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hemolytic-Uremic Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
16 HEMOLYTIC-UREMIC SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEMOLYTIC-UREMIC SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEMOLYTIC-UREMIC SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEMOLYTIC-UREMIC SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEMOLYTIC-UREMIC SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEMOLYTIC-UREMIC SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HEMOLYTIC-UREMIC SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEMOLYTIC-UREMIC SYNDROME - UNMET NEEDS
10 HEMOLYTIC-UREMIC SYNDROME - KEY ENDPOINTS OF TREATMENT
11 HEMOLYTIC-UREMIC SYNDROME - MARKETED PRODUCTS
11.1 List of Hemolytic-Uremic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Soliris (Eculizumab) - Alexion AstraZencea Rare Disease
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Ultomiris (Ravulizumab) - Alexion AstraZeneca Rare Disease
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEMOLYTIC-UREMIC SYNDROME - PIPELINE DRUGS
12.1 List of Hemolytic-Uremic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Crovalimab - Chugai Pharmaceutical/Roche
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Iptacopan - Novartis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 NM8074 - NovelMed Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEMOLYTIC-UREMIC SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEMOLYTIC-UREMIC SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEMOLYTIC-UREMIC SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hemolytic-Uremic Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hemolytic-Uremic Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hemolytic-Uremic Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hemolytic-Uremic Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hemolytic-Uremic Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hemolytic-Uremic Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hemolytic-Uremic Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hemolytic-Uremic Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hemolytic-Uremic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hemolytic-Uremic Syndrome - Access and Reimbursement Overview
16 HEMOLYTIC-UREMIC SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEMOLYTIC-UREMIC SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEMOLYTIC-UREMIC SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
